Valuation: Lundbeck

Market Cap 40.4B 6.23B 5.4B 5.06B 4.62B 8.69B 595B 8.83B 59.63B 23.28B 298B 23.4B 22.89B 993B P/E 2026 *
9.18x
P/E 2027 * 9.17x
Enterprise Value 44.48B 6.86B 5.95B 5.58B 5.08B 9.57B 655B 9.72B 65.65B 25.63B 328B 25.76B 25.2B 1,094B EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.56x
Free-Float
30.75%
Yield 2026 *
3.58%
Yield 2027 * 3.65%
1 day+0.72%
1 week+1.08%
Current month+1.36%
1 month+0.27%
3 months+1.08%
6 months+7.16%
Current year-2.86%
1 week 5.48
Extreme 5.475
5.61
1 month 5.36
Extreme 5.355
5.74
Current year 4.85
Extreme 4.852
6.26
1 year 4.85
Extreme 4.852
6.4
3 years 3.67
Extreme 3.666
6.62
5 years 3.26
Extreme 3.259
8.85
10 years 3.26
Extreme 3.259
8.85
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 66 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%+1.08% - - 6.19B
-2.51%-1.69%+29.18%+94.68% 102B
-1.25%-2.70%+56.12%+150.31% 54.46B
+0.34%+0.34%+4.55%+271.43% 24.09B
+1.33%+2.13%-11.64%-12.97% 8.23B
+0.20%+6.25%-31.86%-25.03% 7.67B
-0.36%-1.47%-13.78%-21.73% 6.66B
+0.77%+1.16%+18.04%+17.19% 6.19B
+0.50%-3.46%-5.99%+20.40% 4.94B
+0.99%+2.83%-5.57%-4.04% 3.73B
Average +0.09%-0.90%+4.34%+54.47% 24.27B
Weighted average by Cap. -1.29%-1.61%+26.49%+110.67%

Financials

2026 *2027 *
Net sales 25.84B 3.99B 3.45B 3.24B 2.95B 5.56B 380B 5.65B 38.14B 14.89B 190B 14.96B 14.64B 635B 25.86B 3.99B 3.46B 3.24B 2.96B 5.56B 381B 5.65B 38.17B 14.9B 191B 14.98B 14.65B 636B
Net income 4.56B 704M 610M 572M 521M 981M 67.14B 996M 6.73B 2.63B 33.61B 2.64B 2.58B 112B 4.59B 708M 614M 575M 524M 987M 67.55B 1B 6.77B 2.64B 33.81B 2.66B 2.6B 113B
Net Debt 4.08B 629M 545M 511M 466M 877M 60.06B 891M 6.02B 2.35B 30.06B 2.36B 2.31B 100B -35.98M -5.55M -4.81M -4.51M -4.11M -7.74M -530M -7.86M -53.12M -20.74M -265M -20.84M -20.39M -885M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
26-08-13 €5.610 +0.72%
26-08-12 €5.570 +0.54%
26-08-11 €5.540 -0.45%
26-08-10 €5.565 +0.18%
26-08-07 €5.555 +0.09%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.00DKK
Average target price
48.12DKK
Spread / Average Target
+14.58%

Quarterly revenue - Rate of surprise